When the Cytoskeleton Fails: Primary Structural Defects Underlying Disorders with Neurological Involvement
- 1Department of Histology-Embryology, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece
Abstract
Cytoskeletal disorders affecting the nervous system are a diverse group of diseases that display a wide variety of clinical manifestations. Mutations in genes encoding cytoskeletal components disrupt the structural and functional integrity of this complex network, impairing normal development and function of the central and peripheral nervous systems. There are also certain diseases which lead to progressive neurodegeneration, and others which result from an interplay of multiple molecular pathways. This review outlines the primary cytoskeletal disorders affecting the nervous system. To provide a comprehensive overview, these diseases are categorized by their predominantly affected cytoskeletal component—namely microtubules, actin filaments, intermediate filaments, and cytoskeleton-associated proteins. Each category highlights the broader pathophysiological context of the underlying defect rather than an isolated structural disturbance. A deeper understanding of the complex pathophysiology of these disorders may contribute to the discovery of potential therapeutic targets, since current medical management primarily provides symptomatic relief or slows their progression.
Related
- Simultaneous multi-task assessment of five neurological language disorders via cross-corpus multimodal learning
- Roles of endogenous retrovirus- and other LTR retrotransposon-derived proteins and peptides in neurological disorders, oncogenesis, and host defense
- Glymphatic system impairment in neurological disorders: potential mechanisms and therapeutic targets
- Factors underlying creativity show distinct genetic architecture and genetic correlations with psychiatric disorders
- Pulling Illusion in Individuals with Neurological Disorders
BibTeX
@article{terzopoulos2026when,
title = {{When the Cytoskeleton Fails: Primary Structural Defects Underlying Disorders with Neurological Involvement}},
author = {Gerasimos Terzopoulos and Evangelos Axarloglou and Evangelie Sintou and Anna Makridou and Sofia Gargani and Soultana Meditskou and Maria Eleni Manthou and Paschalis Theotokis and Iasonas Dermitzakis},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = sep,
doi = {10.3390/ijms27198782},
url = {https://www.mdpi.com/1422-0067/27/19/8782},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - When the Cytoskeleton Fails: Primary Structural Defects Underlying Disorders with Neurological Involvement
AU - Gerasimos Terzopoulos
AU - Evangelos Axarloglou
AU - Evangelie Sintou
AU - Anna Makridou
AU - Sofia Gargani
AU - Soultana Meditskou
AU - Maria Eleni Manthou
AU - Paschalis Theotokis
AU - Iasonas Dermitzakis
PY - 2026
DA - 2026/09/30
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27198782
UR - https://www.mdpi.com/1422-0067/27/19/8782
AB - Cytoskeletal disorders affecting the nervous system are a diverse group of diseases that display a wide variety of clinical manifestations. Mutations in genes encoding cytoskeletal components disrupt the structural and functional integrity of this complex network, impairing normal development and function of the central and peripheral nervous systems. There are also certain diseases which lead to progressive neurodegeneration, and others which result from an interplay of multiple molecular pathways. This review outlines the primary cytoskeletal disorders affecting the nervous system. To provide a comprehensive overview, these diseases are categorized by their predominantly affected cytoskeletal component—namely microtubules, actin filaments, intermediate filaments, and cytoskeleton-associated proteins. Each category highlights the broader pathophysiological context of the underlying defect rather than an isolated structural disturbance. A deeper understanding of the complex pathophysiology of these disorders may contribute to the discovery of potential therapeutic targets, since current medical management primarily provides symptomatic relief or slows their progression.
SN - 1422-0067
ER -